New Strategies in Bladder Cancer: A Second Coming for Immunotherapy

Urothelial bladder cancer (UBC) remains one of the most common and deadly cancers worldwide, and platinum-based chemotherapy, which has been the standard-of-care in metastatic bladder cancer, has had limited success in improving outcomes for patients. The recent development and translation of therap...

Full description

Saved in:
Bibliographic Details
Published inClinical cancer research Vol. 22; no. 4; pp. 793 - 801
Main Authors Ghasemzadeh, Ali, Bivalacqua, Trinity J, Hahn, Noah M, Drake, Charles G
Format Journal Article
LanguageEnglish
Published United States 15.02.2016
Subjects
Animals
Cancer Vaccines - therapeutic use
Combined Modality Therapy
Humans
Immunotherapy
Tumor Microenvironment - immunology
Urinary Bladder Neoplasms - immunology
Urinary Bladder Neoplasms - therapy
Online AccessGet full text

Cover

More Information
Summary:Urothelial bladder cancer (UBC) remains one of the most common and deadly cancers worldwide, and platinum-based chemotherapy, which has been the standard-of-care in metastatic bladder cancer, has had limited success in improving outcomes for patients. The recent development and translation of therapeutic strategies aimed at harnessing the immune system have led to durable and prolonged survival for patients with several different cancers, including UBC. In this review, we discuss new findings in bladder cancer immunotherapy, including recent successes with immune checkpoint blockade. We also discuss therapeutic cancer vaccines and highlight several additional immunotherapy modalities in early stages of development.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.ccr-15-1135